35 completed, 6 terminated, 3 unknown, 1 active not recruiting. 27 Phase 3, 16 Phase 2, 4 Phase 4, 1 Phase 1.
Follow Dr. Falk Pharma GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) norucholic acid - Primary Sclerosing Cholangitis | Phase 3 | Not yet recruiting | Dr. Falk Pharma GmbH | 120 | 2025-03-01 | 2025-03-20 |
| Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease ZED1227 + SIGE, Placebo - Celiac Disease | Phase 2 | Recruiting | Dr. Falk Pharma GmbH | 356 | 2024-06-10 | 2026-04-02 |
| Mesalazine Oral Suspension in Active Eosinophilic Esophagitis Mesalamine Oral Product - Eosinophilic Esophagitis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 5 | 2023-02-09 | 2023-09-07 |
| Different Doses of Naronapride vs. Placebo in Gastroparesis Naronapride, Placebo - Gastroparesis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 328 | 2023-01-03 | 2026-10-07 |
| Different Doses of ZED1227 vs. Placebo in NAFLD ZED1227, Placebo - NAFLD, Liver Fibrosis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 186 | 2022-04-19 | 2024-05-14 |
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE Budesonide - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | Dr. Falk Pharma GmbH | 308 | 2021-05-21 | 2026-08-28 |
| Norursodeoxycholic Acid vs. Placebo in NASH norUrsodeoxycholic acid - Nonalcoholic Steatohepatitis | Phase 2 | Unknown | Dr. Falk Pharma GmbH | 363 | 2019-07-08 | 2024-02-20 |
| A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis ST-0529 - Colitis, Ulcerative | Phase 2 | Terminated | Sublimity Therapeutics Holdco Limited | 235 | 2019-01-24 | 2021-05-07 |
| norUrsodeoxycholic Acid vs Placebo in PSC norUrsodeoxycholic Acid - Primary Sclerosing Cholangitis | Phase 3 | Unknown | Dr. Falk Pharma GmbH | 303 | 2018-02-08 | 2024-08-06 |
| Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Budesonide 0.5mg orodispersible tablet twice daily, Budesonide 1mg orodispersible tablet twice daily, Placebo orodispersible tablet twice daily - Eosinophilic Esophagitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 204 | 2016-01-15 | 2021-10-07 |
| Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Budesonide 1mg orodispersible tablet twice daily, Placebo orodispersible tablet twice daily - Eosinophilic Esophagitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 88 | 2015-11-11 | 2017-02-03 |
| Budesonide 9 mg Capsules in Active UC Budesonide - Colitis, Ulcerative | Phase 2 | Completed | Dr. Falk Pharma GmbH | 60 | 2015-10-01 | 2017-07-26 |
| Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) LT-02, Placebo, Mesalamine - Ulcerative Colitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 150 | 2014-10-01 | 2020-01-27 |
| Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis LT-02, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Dr. Falk Pharma GmbH | 468 | 2014-07-21 | 2017-02-09 |
| Budesonide for Induction of Remission in Incomplete Microscopic Colitis Budesonide granules 9 mg, Placebo granules - Incomplete Microscopic Colitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 44 | 2014-05-01 | 2020-07-22 |
| Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis Budesonide 2 mg suppository, Budesonide 4 mg suppository, Mesalazine 1 g suppository - Proctitis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 320 | 2013-09-01 | 2019-05-07 |
| Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis Rifamycin SV-MMX® 400 mg b.i.d., Rifamycin SV-MMX® 600 mg t.i.d., Rifamycin SV-MMX® Placebo - Uncomplicated Diverticulitis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 204 | 2013-08-01 | 2017-07-26 |
| TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC) Mesalazine - TID 1000 mg, Mesalazine - TID 2x 500 mg - Active Ulcerative Colitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 306 | 2013-01-01 | 2016-06-01 |
| Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis norUDCA, Placebo - Primary Sclerosing Cholangitis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 159 | 2012-12-01 | 2016-08-03 |
| Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Mucofalk - Gastroesophageal Reflux Disease | Phase 4 | Completed | Russian Academy of Medical Sciences | 36 | 2012-04-01 | 2019-08-13 |
Showing 20 of 47. Sign in to see all of them.
Colitis, Ulcerative (7) · Eosinophilic Esophagitis (5) · Crohn Disease (4) · Cholangitis, Sclerosing (3) · Colitis, Collagenous (2) · Colitis, Lymphocytic (2) · Diverticulitis (2) · Graft vs Host Disease (2) · Liver Cirrhosis, Biliary (2) · Non-alcoholic Fatty Liver Disease (2) · Celiac Disease (1) · Cholecystolithiasis (1) · Colic (1) · Colitis, Microscopic (1) · Diabetes Mellitus (1)
Budesonide (19) · Mesalamine (12) · Ursodeoxycholic Acid (3) · 24-norursodeoxycholic acid (2) · BID protein, human (2) · ZED1227 (2) · ATI 7505 (1) · Azathioprine (1) · Ciprofloxacin (1) · Cyclosporine (1) · DNER protein, human (1) · Prednisone (1) · Psyllium (1) · Suppositories (1)
Germany (34) · Austria (4) · United States (4) · Israel (3) · France (2) · Netherlands (2) · Russia (2) · Spain (2) · Sweden (2) · United Kingdom (2) · Belarus (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Ecuador (1)
Wolfgang Kruis, Professor (4) · Michael Trauner, MD (3) · Ralph Mueller, PhD (3) · Ralph Mueller, Dr (2) · Stephan Miehlke, Prof. (2) · Stephan Miehlke, Professor (2) · Alfredo J Lucendo, MD, PhD (1) · Andreas Tromm, Professor (1) · Axel Dignass, MD (1) · Axel Dignass, Prof Dr (1) · Axel Dignass, Prof. (1) · Britta Siegmund, Professor (1) · Christian Rust, MD (1) · Christoph H Gleiter, MD (1)
PMID 28543263, PMID 28707787, PMID 28707796, PMID 37806372, PMID 16729326, PMID 18832520, PMID 20551460, PMID 20600032, PMID 21070781, PMID 21138455, PMID 21453882, PMID 21703973, PMID 22300693, PMID 22414767, PMID 23414061, PMID 23810723, PMID 24440672, PMID 24534142, PMID 25425214, PMID 25425655, PMID 25543678, PMID 25792708, PMID 27121784, PMID 28529147, PMID 29702300, PMID 30195447, PMID 30922997, PMID 32721437, PMID 32950590, PMID 33028169, PMID 38977324, PMID 39694205
2004 (2), 2008 (2), 2009 (2), 2014 (2), 2023 (2)